You are here

  • Home
  • Archive
  • Volume 7, Issue 5
  • Warfarin combined with low dose aspirin in myocardial infarction did not provide clinical benefit beyond that of aspirin alone

Article Text

Article menu
Download PDFPDF
Therapeutics
Warfarin combined with low dose aspirin in myocardial infarction did not provide clinical benefit beyond that of aspirin alone

https://doi.org/10.1136/ebm.7.5.140

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2002) Circulation 105, 557; Fiore LD, Ezekowitz MD, Brophy MT, et al., for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group.. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study.. Feb 5;. :. –63..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In patients who have survived an acute myocardial infarction (MI), is warfarin combined with aspirin more effective than aspirin alone?

    Design

    Randomised (allocation concealed*), unblinded,* controlled trial with a median 2.7 years of follow up.

    Setting

    78 Department of Veterans Affairs medical centres in the US.

    Patients

    5059 patients (median age 62 y, 98% men) who had an acute MI within the previous 14 days. Exclusion criteria included comorbid conditions that limited life expectancy to <2 years, ongoing bleeding, drug or alcohol dependence, and hypersensitivity to aspirin or warfarin. Vital status was obtained for 99% of the patients.

    Intervention

    2522 patients were assigned to warfarin (target international normalised ratio [INR] 1.5 to 2.5 IU) plus aspirin (81 mg/d), and 2537 were assigned to aspirin alone (162 mg/d).

    Main outcome measures

    The primary outcome was all-cause mortality. Secondary outcomes were recurrent MI, stroke, …

    View Full Text

    Footnotes

    • Sources of funding: Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; DuPont Pharmaceuticals; Bayer Pharmaceuticals.

    • For correspondence: Dr L Fiore, VA Boston Healthcare System, Boston, Massachusetts, USA. louis.fiore{at}med.va.gov

    • ↵* See glossary.